ClinicalTrials.gg
Sign In
Biological

Therapeutic Tumor Infiltrating Lymphocytes clinical trials

studies test it
48
open now
24
in phase 3
0
first study started
1999

How each study uses Therapeutic Tumor Infiltrating Lymphocytes is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Therapeutic Tumor Infiltrating Lymphocytes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tumor Infiltrating Lymphocytes (TIL)
16
Tumor Infiltrating Lymphocytes
7
TIL infusion
5
TIL
5
TILs
4

Development codes

NEOG-100
1

Studies by the year they started

48 studies that test it; most in 2021 (8)

Studies that test Therapeutic Tumor Infiltrating Lymphocytes, by start year
YearStudies
19991
20081
20091
20101
20112
20133
20143
20151
20162
20172
20181
20192
20204
20218
20223
20232
20245
20255
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
11
Phase 1
23
Phase 2
26
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Melanoma
11
Uterine Cervical Neoplasms
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Glioblastoma
2
Uveal Melanoma
1
Biliary Tract Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Renal Cell
1

Who runs them

Industry 11 · Other 37

Shanghai Juncell Therapeutics (7) · Inge Marie Svane (5) · National Cancer Institute (NCI) (5) · Essen Biotech (5) · Udai Kammula (3) · City of Hope Medical Center (2) · Christian Hinrichs (2) · H. Lee Moffitt Cancer Center and Research Institute (2)

Often tested with

Tested in the same studies.

Fludarabine (8) · Cyclophosphamide (8) · Interleukin-2 (3) · Aldesleukin (3) · Pembrolizumab (2) · Fludarabine phosphate (1) · Vemurafenib (1) · Interleukins (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8

Studies that test Therapeutic Tumor Infiltrating Lymphocytes.

Studies

Open first, then newest update. How each study uses Therapeutic Tumor Infiltrating Lymphocytes is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 48

See all 48 studies that test Therapeutic Tumor Infiltrating Lymphocytes →

Given beside what is tested · 15 — Therapeutic Tumor Infiltrating Lymphocytes is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 16, 2026.

Stopped1